Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate

Experimental Hematology

Volumn 31, Issue 11, 2003, Pages 1073-1080

  Tipping, Alex J ^a   Deininger, Michael W ^b   Goldman, John M ^a   Melo, Junia V ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ALPHA TUBULIN; ANGIOPOIETIN 1; AZUROCIDIN; BCR ABL PROTEIN; BETA2 INTEGRIN; CARBOXYLESTERASE; CARRIER PROTEIN; CYCLINE; GALANIN; GLIA MATURATION FACTOR; GLYCOGEN SYNTHASE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN ALPHA; IMATINIB; NICOTINAMIDE METHYLTRANSFERASE; OXYGENASE; PHOSPHOPROTEIN; PROCOLLAGEN; PROCOLLAGEN C PROTEINASE; PROSAPOSIN; PROSTAGLANDIN SYNTHASE; PROTEASOME; PROTEIN; PROTEIN BCL 2; RIBOSOME PROTEIN; SOMATOMEDIN BINDING PROTEIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1; TREFOIL PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CELL CLONE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; DRUG EXPOSURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SUBUNIT; FUSION GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENOME ANALYSIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONOTHERAPY; NUCLEOTIDE SEQUENCE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION;

EID: 0142227047     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2003.08.006     Document Type: Article

References (37)

1. Kantarjian H.M., Cortes J., O'Brien S., et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 99:2002;3547-3553.
2. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 99:2002;3530-3539.
3. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 99:2002;1928-1937.
4. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:2001;876-880.
5. + cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 96:2000;1070-1079.
6. Weisberg E., Griffin J.D. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 95:2000;3498-3505.
7. + acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 99:2002;3472-3475.
8. Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 16:2002;2190-2196.
9. Shah N., Nicoll J., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:2002;117.
10. Hofmann W.K., de Vos S., Elashoff D., et al. Relation between resistance of Philadelphia chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet. 359:2002;481-486.
11. Donato N.J., Wu J.Y., Stapley J., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 101:2003;690-698.
12. Kaneta Y., Kagami Y., Katagiri T., et al. Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. Jpn J Cancer Res. 93:2003;849-856.
13. Khatri P., Draghici S., Ostermeier G.C., Krawetz S.A. Profiling gene expression using onto-express. Genomics. 79:2002;266-270.
14. Araujo H., Danziger N., Cordier J., Glowinski J., Chneiweiss H. Characterization of PEA-15, a major substrate for protein kinase C in astrocytes. J Biol Chem. 268:1993;5911-5920.
15. Hwang S., Kuo W.L., Cochran J.F., et al. Assignment of HMAT1, the human homolog of the murine mammary transforming gene (MAT1) associated with tumorigenesis, to 1q21.1, a region frequently gained in human breast cancers. Genomics. 42:1997;540-542.
16. Bera T.K., Guzman R.C., Miyamoto S., et al. Identification of a mammary transforming gene (MAT1) associated with mouse mammary carcinogenesis. Proc Natl Acad Sci U S A. 91:1994;9789-9793.
17. Sacchi N., Watson D.K., Guerts van Kessel A.H., et al. Hu-ets-1 and Hu-ets-2 genes are transposed in acute leukemias with (4;11) and (8;21) translocations. Science. 231:1986;379-382.
18. Le Beau M.M., Rowley J.D., Sacchi N., Watson D.K., Papas T.S., Diaz M.O. Hu-ets-2 is translocated to chromosome 8 in the t(8;21) in acute myelogenous leukemia. Cancer Genet Cytogenet. 23:1986;269-274.
19. Sevilla L., Aperlo C., Dulic V., et al. The Ets2 transcription factor inhibits apoptosis induced by colony-stimulating factor 1 deprivation of macrophages through a bcl-xL- dependent mechanism. Mol Cell Biol. 19:1999;2624-2634.
20. Derynck R., Goeddel D.V., Ullrich A., et al. Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors. Cancer Res. 47:1987;707-712.
21. Dickson R.B., Kasid A., Huff K.K., et al. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 β-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci U S A. 84:1987;837-841.
22. Duan H., Dixit V.M. RAIDD is a new "death" adaptor molecule. Nature. 385:1997;86-89.
23. Felmer R., Horvat S., Clinton M., Clark A.J. Overexpression of Raidd cDNA inhibits differentiation of mouse preadipocytes. Cell Prolif. 36:2003;45-54.
24. Lesne S., Blanchet S., Docagne F., et al. Transforming growth factor-β1-modulated cerebral gene expression. J Cereb Blood Flow Metab. 22:2002;1114-1123.
25. Valable S., Bellail A., Lesne S., et al. Angiopoietin-1-induced PI3-kinase activation prevents neuronal apoptosis. FASEB J. 17:2003;443-445.
26. Hamamori Y., Sartorelli V., Ogryzko V., et al. Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell. 96:1999;405-413.
27. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12:1998;599-606.
28. Hjiantoniou E., Iseki S., Uney J.B., Phylactou L.A. DNazyme-mediated cleavage of Twist transcripts and increase in cellular apoptosis. Biochem Biophys Res Commun. 300:2003;178-181.
29. Kasof G.M., Goyal L., White E. Btf, a novel death-promoting transcriptional repressor that interacts with bcl-2-related proteins. Mol Cell Biol. 19:1999;4390-4404.
30. Cmarko D., Verschure P.J., Otte A.P., Van Driel R., Fakan S. Polycomb group gene silencing proteins are concentrated in the perichromatin compartment of the mammalian nucleus. J Cell Sci. 116:2003;335-343.
31. van Lohuizen M., Verbeek S., Scheijen B., Wientjens E., van der Gulden H., Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell. 65:1991;737-752.
32. Haupt Y., Alexander W.S., Barri G., Klinken S.P., Adams J.M. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell. 65:1991;753-763.
33. Fathallah D.M., Jamal T., Barbouche M.R., Bejaoui M., Hariz M.B., Dellagi K. Two novel frame shift, recurrent and de novo mutations in the ITGB2 (CD18) gene causing leukocyte adhesion deficiency in a highly inbred North African population. J Biomed Biotechnol. 1:2001;114-121.
34. Jensen M.R., Audolfsson T., Factor V.M., Thorgeirsson S.S. In vivo expression and genomic organization of the mouse cyclin I gene (Ccni). Gene. 256:2000;59-67.
35. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346:2002;645-652.
36. Gambacorti-Passerini C.B., Gunby R.H., Piazza R., Galietta A., Rostagno R., Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia chromosome-positive leukemias. Lancet Oncol. 4:2003;75-85.
37. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 348:2003;994-1004.